stockrowActinium Pharmaceuticals, Inc.
ATNM Healthcare Biotechnology
Actinium Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $90,000.00, up 11.1% from fiscal 2023.
- Revenue
- +77,677.8%
- EPS
- +504.6%
- Free cash flow
- −4.91%
Quarter to June 2026, against a year earlier
Follow ATNM
Alert me
Actinium Pharmaceuticals, Inc. (ATNM) Beneish M-score
Actinium Pharmaceuticals, Inc.'s Beneish M-score for fiscal 2025 cannot be worked out: no comparable prior fiscal year (a missing year or a changed year end).
Beneish M-score, annual
Annual newest first
| Period | Beneish M-score | Change (points) |
|---|
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Days’ sales in receivables index | — | — | n/a | — |
| Gross margin index | — | — | n/a | — |
| Asset quality index Asset quality not computable — index set to 1 | 1.00 | — | Set to 1 | 0.40 |
| Sales growth index | — | — | n/a | — |
| Depreciation index Depreciation not reported — index set to 1 | 1.00 | — | Set to 1 | 0.12 |
| SG&A index SG&A not reported — index set to 1 | 1.00 | — | Set to 1 | −0.17 |
| Total accruals to total assets | (0.18) | — | −0.84 | |
| Leverage index | — | — | n/a | — |
| Beneish M-score | n/a — no comparable prior fiscal year (a missing year or a changed year end) | — | ||
How the Beneish M-score works
M = −4.84 + 0.920 × DSRI + 0.528 × GMI + 0.404 × AQI + 0.892 × SGI + 0.115 × DEPI − 0.172 × SGAI + 4.679 × TATA − 0.327 × LVGI (Beneish, 1999): eight changes in the accounts from one fiscal year to the next, which the model weighs for the pattern seen in companies that later restated their earnings. Higher is worse.
| below −2.22 | Low — no pattern the model associates with manipulation |
|---|---|
| −2.22 to −1.78 | Elevated |
| above −1.78 | Flagged by the model |
−1.78 is the cut-off usually quoted from the paper, −2.22 a common conservative one. A statistical screen, not a finding of wrongdoing.
When asset quality, depreciation or SG&A cannot be worked out, that index is set to 1, as Beneish did, and the breakdown says so; with all three missing there is no score. Depreciation includes amortisation, and asset quality leaves out securities. Not worked out for banks, insurers and REITs.
Beneish M-score against peers
| Company | Beneish M-score |
|---|---|
| SGMOQ Sangamo Therapeutics, Inc. compare | −5.1× |
| ATHE Alterity Therapeutics Limited - Sponsored ADR compare | 30.2× |
| BMEA Biomea Fusion, Inc. compare | — |
| ATNM Actinium Pharmaceuticals, Inc. | — |
| LONA LeonaBio, Inc. compare | — |
| GANX Gain Therapeutics, Inc. compare | — |
| HYPD Hyperion DeFi, Inc. compare | — |
| DWTX Dogwood Therapeutics, Inc compare | — |
| SER Serina Therapeutics, Inc. compare | — |
What Beneish M-score is
The Beneish M-Score combines eight year-on-year changes in the accounts into a statistical screen for patterns seen in companies that overstated earnings.
−4.84 + 0.920 × DSRI + 0.528 × GMI + 0.404 × AQI + 0.892 × SGI + 0.115 × DEPI − 0.172 × SGAI + 4.679 × TATA − 0.327 × LVGI